On September 30 2025, ImmuCell Corporation (Nasdaq: ICCC) announced that it has selected Olivier te Boekhorst as its next President and CEO, with a start date of November 1 2025. Te Boekhorst is currently an Operating Partner at ARCHIMED and Chair of the Board of SeqCenter; he previously held senior leadership roles at IDEXX Laboratories, where he led M&A activities and grew the livestock and dairy diagnostics divisions.
In the announcement, current President and CEO Michael F. Brigham said, “Change is good, and handing off leadership to Olivier at this time is an exciting next step for the Company.” Te Boekhorst replied, “I am excited to join the ImmuCell organization as President and CEO at this pivotal time, with exciting opportunities for First Defense® and Re‑Tain® ahead of us.” The company expects the new CEO’s experience in livestock diagnostics and M&A to accelerate growth of its core products.
The terms of te Boekhorst’s employment include two initial stock‑option awards: a non‑qualified option to purchase 76,673 shares granted on September 16 2025, exercisable only if he commences employment by November 30 2025, and a second award of up to 85,000 shares granted after commencement, comprising incentive and non‑qualified options with a 10‑year term. He will also serve as Special Advisor to the CEO for at least two months and remain on the board until the next annual meeting of stockholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.